CAPS patients also display elevated levels of ASC and mature IL-1β in peripheral blood mononuclear cells and treatment of mononuclear cells ex vivo with MCC950 reduced mature IL-1β production, highlighting the therapeutic potential of NLRP3 small molecule inhibitors [56•]. This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.